VisEn Medical, Inc.

VisEn Medical Introduces NanoSPARKS(TM) Line of Optical Imaging Probes

VisEn Medical Introduces NanoSPARKS(TM) Line of Optical Imaging Probes

March 27, 2006

ORLANDO, Fla.--(BUSINESS WIRE)--March 27, 2006--VisEn Medical, a leader in optical imaging technologies for biomedical research, today announced the introduction of the first three products in a new line of optical imaging probes. Called NanoSPARKS(TM), the new product line uses super-bright, targetable, biocompatible nanoparticles for imaging of biological and molecular processes in vivo.

BG Medicine, Inc.

BG Medicine to Conduct Joint Biomarker Discovery Study for Muscle Toxicity with Mitsubishi Pharma Corporation

BG Medicine to Conduct Joint Biomarker Discovery Study for Muscle Toxicity with Mitsubishi Pharma Corporation

March 28, 2006

Waltham, MA -- March 28, 2006 -- BG Medicine Inc. today announced a collaborative preclinical research study into the biochemical origins of muscle toxicity and associated biomarkers with Mitsubishi Pharma Corporation (Osaka, Japan).

Ensemble Therapeutics Corporation

Ensemble Discovery Corporation Appoints Laurence Reid Chief Business Officer

Ensemble Discovery Corporation Appoints Laurence Reid Chief Business Officer

March 28, 2006

Cambridge, MA (March 28, 2006) - Ensemble Discovery Corporation today announced the appointment of Laurence E. Reid, Ph.D. as Chief Business Officer. In this position, Dr. Reid will lead strategic business planning and corporate development activities for the Company. He will work closely with the other members of Ensemble’s executive team to align business strategies and research and development efforts.

Affinnova, Inc.

Affinnova Awarded Broad Patent for Interactive Product Design Technology

Affinnova Awarded Broad Patent for Interactive Product Design Technology

March 29, 2006

Breakthrough technology empowers marketers to harness consumer input in the development of innovative products

BG Medicine, Inc.

FDA's Accomplishments in 2005 Highlight BG Medicine's Role in Liver Toxicology Biomarker Study

FDA's Accomplishments in 2005 Highlight BG Medicine's Role in Liver Toxicology Biomarker Study

March 29, 2006

In its recent report on accomplishments during this last year, the FDA highlighted their agreement in October of 2005 with Flagship portfolio company BG Medicine as an important example of their Critical Path initiative. You can read more about the project on its website.

Full text of the FDA's press release follows:

FDA's Accomplishments in 2005

Zalicus

CombinatoRx Announces Discovery of Novel Synergistic Combination Leads for Glioblastoma

CombinatoRx Announces Discovery of Novel Synergistic Combination Leads for Glioblastoma

April 3, 2006

Data presented at AACR

Interactive Supercomputing Corporation

New Opteron-based Star-P Software Brings Supercomputing to the Masses

New Opteron-based Star-P Software Brings Supercomputing to the Masses

April 17, 2006

ISC's interactive parallel computing platform to run on 64-bit AMD Opteron-based high performance computers

Doug Levinson Joins Flagship Ventures

Doug Levinson Joins Flagship Ventures

April 17, 2006


We are pleased to announce the recent addition of Doug Levinson, PhD, to the Flagship Ventures team as Partner. He brings to Flagship’s venture investment and new venture creation activities over fifteen years of experience in the biotech industry.

Zalicus

CombinatoRx Reports Positive Results for CRX-170 in Phase 2 Proof-of-Concept Asthma Clinical Trial

CombinatoRx Reports Positive Results for CRX-170 in Phase 2 Proof-of-Concept Asthma Clinical Trial

April 18, 2006

Novel Combination Drug Candidate Demonstrates Clinical Benefit on Forced Expiratory Volume (FEV1)

Acceleron Pharma, Inc.

Acceleron Pharma Appoints Matthew L. Sherman, M.D. as Chief Medical Officer

Acceleron Pharma Appoints Matthew L. Sherman, M.D. as Chief Medical Officer

May 16, 2006

Dr. Sherman's Expertise in Building a Clinical Development Organization and Advancing Programs Through Regulatory Approval a Key Addition to the Management Team

5/16/2006 - Acceleron Pharma, Inc., a biopharmaceutical company focused on developing and commercializing therapeutics based on its novel tissue growth factor platform, today announced the appointment of Matthew L. Sherman, M.D. as Senior Vice President and Chief Medical Officer.